These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
160 related articles for article (PubMed ID: 1684702)
21. Present state of the controversy about regular inhaled beta-agonists in asthma. Giuntini CG; Paggiaro PL Eur Respir J; 1995 May; 8(5):673-8. PubMed ID: 7656934 [No Abstract] [Full Text] [Related]
22. Combination inhaled corticosteroid and long-acting β2-agonist use and severe asthma exacerbations. Pedersen S; O'Byrne PM J Allergy Clin Immunol; 2012 May; 129(5):1280-1. PubMed ID: 22464645 [No Abstract] [Full Text] [Related]
23. Perception versus reality: the saga of inhaled asthma controller medication and fetal risk. Steinberg JA J Allergy Clin Immunol; 2015 Jan; 135(1):131-2. PubMed ID: 25445824 [No Abstract] [Full Text] [Related]
24. Re: "Confounding by indication and channeling over time: the risks of beta2-agonists". Pearce N; Beasley R; Crane J; Burgess C Am J Epidemiol; 1997 Nov; 146(10):885-7. PubMed ID: 9384211 [No Abstract] [Full Text] [Related]
26. Long-and short-acting beta 2-adrenergic agonists. Effects on airway function in patients with asthma. Busse WW Arch Intern Med; 1996 Jul; 156(14):1514-20. PubMed ID: 8687259 [TBL] [Abstract][Full Text] [Related]
27. Long-acting beta-agonists with and without inhaled corticosteroids and catastrophic asthma events. Salpeter SR; Wall AJ; Buckley NS Am J Med; 2010 Apr; 123(4):322-8.e2. PubMed ID: 20176343 [TBL] [Abstract][Full Text] [Related]
28. An update on the safety of long-acting beta-agonists in asthma patients using inhaled corticosteroids. Salpeter SR Expert Opin Drug Saf; 2010 May; 9(3):407-19. PubMed ID: 20408768 [TBL] [Abstract][Full Text] [Related]
29. Asthma control in a random sample of New Zealand adolescent asthmatics. van Dalen CJ; Harding E; Parkin J; Blakey K; Cheng S; Pearce NE; Douwes J J Asthma; 2007 May; 44(4):261-6. PubMed ID: 17530523 [TBL] [Abstract][Full Text] [Related]
30. Potential for tolerance, morbidity, and mortality resulting from regular use of beta 2-adrenergic agonists in asthma. Giangrasso T South Med J; 1997 Feb; 90(2):173-9. PubMed ID: 9042167 [TBL] [Abstract][Full Text] [Related]
31. The saga of the New Zealand asthma mortality epidemic. N Z Med J; 1995 Mar; 108(995):91. PubMed ID: 7661939 [No Abstract] [Full Text] [Related]
32. The use of beta agonists and the risk of death and near death from asthma. Pearce N J Clin Epidemiol; 2009 Jun; 62(6):582-7. PubMed ID: 19422997 [No Abstract] [Full Text] [Related]
33. When should a long acting {beta} agonist be added to an inhaled corticosteroid? Tattersfield AE Thorax; 2005 Sep; 60(9):710. PubMed ID: 16135676 [No Abstract] [Full Text] [Related]
34. The expanding role of long-acting beta-agonists. Donohue JF Chest; 2000 Aug; 118(2):283-5. PubMed ID: 10936111 [No Abstract] [Full Text] [Related]
35. [Beta-2 adrenergic stimulants in the treatment of asthma: myths and realities]. Maria Y; Moneret-Vautrin DA Rev Pneumol Clin; 1989; 45(5):185-93. PubMed ID: 2576328 [TBL] [Abstract][Full Text] [Related]
36. Summaries for patients. What are the risks of using inhaled long-acting beta-agonist medications for the relief of asthma? Ann Intern Med; 2006 Jun; 144(12):I30. PubMed ID: 16785474 [No Abstract] [Full Text] [Related]
37. Inhaled beta 2-adrenergic agonists in asthma: the evolving dilemma. Hui KP Singapore Med J; 1994 Jun; 35(3):237-9. PubMed ID: 7997893 [TBL] [Abstract][Full Text] [Related]
38. The risk of asthma mortality with inhaled long acting beta-agonists. Wijesinghe M; Perrin K; Harwood M; Weatherall M; Beasley R Postgrad Med J; 2008 Sep; 84(995):467-72. PubMed ID: 18940948 [TBL] [Abstract][Full Text] [Related]
39. [Beta 2-agonists in asthma. New facts on the subject?]. Larsson K Lakartidningen; 1993 Mar; 90(10):909-10. PubMed ID: 8096262 [No Abstract] [Full Text] [Related]